Phase 1 N=61 A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women
Postmenopausal Symptoms
Primary: Number of Participants With Adverse Events — 24; 20; 12; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=36 A Safety Study of AZD4041 in Healthy Participants
Opioid Use Disorder (OUD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 8; 6; 6; 9 Participants
Phase 1 N=26 Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
B-cell Malignancies
Primary: Arm A: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration (AUC0-t) — 1899.32; 921.63; 797.87 h*ng/mL
Phase 1 N=8 A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.
Rare Diseases
Primary: The Maximum Observed Concentration of Emapalumab — 23980 ng/mL
Phase 1 N=15 A Study of Soticlestat and Rifampin in Healthy Adults
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Soticlestat When Administered Alone and With Rifampin — 1364; 176.8 nanogram per milliliter (ng/mL)
Phase 1 N=22 Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
Postmenopausal Osteoporosis
Primary: Abaloparatide Maximum Plasma Concentration (Cmax) on Day 29 — 399.6 picograms/milliliter (pg/mL)
Phase 1 N=20 Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus
Esophageal Squamous Cell Carcinoma
Primary: Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events) — 13 Participants
Phase 1 N=6 A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting
Hepatitis B Virus
Primary: Maximum Observed Plasma Concentration (Cmax) — 8.17 ng/mL
Phase 1 N=44 Intestinal Permeability in Preterm Infants
Prematurity · Intestinal Permeability
Primary: Intestinal Permeability — 0.0731; 0.0720 ratio — p=0.932
Phase 1 N=17 Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Prostate Cancer · Prostatic Neoplasm
Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)
Phase 1 N=16 A Target Occupancy Study With Ritlecitinib.
Healthy
Primary: Percent Target Occupancy for JAK3 — 0.00; 0.00; 72.41; 28.74 percentage of occupancy
Phase 1 N=33 A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Minimum Observed Plasma Concentration (Cmin) Post 10 Weeks of Certolizumab Pegol Dosing — 24.93 micrograms per milliliter (ug/mL)
Phase 1 N=128 Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma · Hepatocellular Carcinoma · Liver Cancer
Primary: Part 1, Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for…
Phase 1 N=6 To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Maximum Tolerated Dose (MTD) of Hydroxychloroquine and Entinostat in Combination With Regorafenib — 1200; 5 mg
Phase 1 N=18 Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of Tepotinib — 15348; 16523 Hours*nanogram per milliliter…